West Pharmaceutical Services, Inc. (NYSE:WST) was upgraded by investment analysts at Jefferies Group LLC from a “hold” rating to a “buy” rating in a report released on Friday, Marketbeat Ratings reports. The brokerage currently has a $115.00 price target on the medical instruments supplier’s stock. Jefferies Group LLC’s price target would indicate a potential upside of 19.90% from the company’s current price.

WST has been the subject of several other research reports. BidaskClub lowered West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. Zacks Investment Research lowered West Pharmaceutical Services from a “hold” rating to a “sell” rating in a research report on Wednesday, July 19th. Two equities research analysts have rated the stock with a sell rating and three have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $98.52.

West Pharmaceutical Services (WST) traded up 4.61% on Friday, hitting $95.91. 761,446 shares of the company were exchanged. West Pharmaceutical Services has a 52 week low of $70.17 and a 52 week high of $99.91. The stock has a 50 day moving average of $87.41 and a 200 day moving average of $89.29. The company has a market capitalization of $7.10 billion, a price-to-earnings ratio of 41.16 and a beta of 1.13.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, July 27th. The medical instruments supplier reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.01. The firm had revenue of $397.60 million during the quarter, compared to analyst estimates of $406.00 million. West Pharmaceutical Services had a return on equity of 14.02% and a net margin of 11.42%. West Pharmaceutical Services’s quarterly revenue was up 2.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.59 EPS. Analysts predict that West Pharmaceutical Services will post $2.68 EPS for the current fiscal year.

TRADEMARK VIOLATION WARNING: This news story was reported by American Banking News and is owned by of American Banking News. If you are viewing this news story on another publication, it was copied illegally and reposted in violation of United States and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2017/09/15/west-pharmaceutical-services-inc-wst-upgraded-by-jefferies-group-llc-to-buy.html.

Several institutional investors and hedge funds have recently bought and sold shares of WST. Acrospire Investment Management LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter worth about $113,000. Citigroup Inc. raised its position in West Pharmaceutical Services by 95.1% in the 2nd quarter. Citigroup Inc. now owns 1,569 shares of the medical instruments supplier’s stock worth $148,000 after buying an additional 765 shares during the last quarter. Harfst & Associates Inc. purchased a new position in West Pharmaceutical Services in the 1st quarter worth about $186,000. Wolverine Trading LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter worth about $200,000. Finally, Nomura Holdings Inc. purchased a new position in West Pharmaceutical Services in the 2nd quarter worth about $201,000. 91.25% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a manufacturer of packaging components and delivery systems for injectable drugs and healthcare products. The Company’s products include vial containment solutions, prefillable systems, self-injection platforms, cartridge systems and components, reconstitution and transfer systems, intradermal delivery solutions, specialty components, and contract manufacturing and analytical services.

Receive News & Ratings for West Pharmaceutical Services Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services Inc. and related companies with MarketBeat.com's FREE daily email newsletter.